FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3085384777> ?p ?o ?g. }

• W3085384777 endingPage "997" @default.
• W3085384777 startingPage "979" @default.
• W3085384777 abstract "Identifying the significant parameters for early progression toward worse prognosis is fundamental for the management of COVID-19 patients. In this Journal, Zhi Lin and colleagues1Lin Z. Long F. Yang Y. Serum ferritin as an independent risk factor for severity in COVID-19 patients.J Infect. 2020 Jun 24; (Epub ahead of print)https://doi.org/10.1016/j.jinf.2020.06.053Abstract Full Text Full Text PDF Scopus (95) Google Scholar recently reported that Chinese patients with severe Sars-CoV2 disease showed higher levels of serum ferritin than patients with not severe one, confirming data from other authors on Chinese2Wu C. Chen X. Cai Y. Xia J. Zhou X. Xu S. et al.Risk Factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 Pneumonia in Wuhan, China.JAMA Intern Med. 2020; Crossref Scopus (5495) Google Scholar,3Henry B.M. de Oliveira M. Benoit S. Plebani M. Lippi G Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.Clin Chem Lab Med. 2020; Crossref Scopus (1200) Google Scholar and Caucasian populations.4Bhatraju P.K. Ghassemieh B.J. Nichols M. Kim R. Jerome K.R. Nalla A.K. Covid-19 in critically ill patients in the Seattle region - case series.N Engl J Med. 2020; https://doi.org/10.1056/NEJMoa2004500Crossref PubMed Scopus (1740) Google Scholar,5Xu X.W. Wu X.X. Jiang X.G. Xu K.J. Ying L.J. Ma C.L. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series.BMJ. 2020; 368: m606https://doi.org/10.1136/bmj.m606Crossref PubMed Scopus (1402) Google Scholar Here we aimed to establish the most suitable panel for routine prognostic serum laboratory testing in COVID-19 patients upon first admission to the Emergency Department. We thus enrolled 141 patients (59 females and 82 males, aging 64,48 ± 16,58 years) diagnosed as COVID-19 by means of real-time polymerase chain reaction testing and admitted to the isolation ward of Emergency Department at Policlinico Umberto I Hospital in Rome, Italy, between March 2020 and June 2020. Serum samples were collected from patients upon admission before starting any treatment and tested by Laboratory Department. Of all patients included, 81 patients (57%) showed mild disease (control group) and 60 (43%) showed acute respiratory distress syndrome (ARDS) and systemic inflammation (severe group). Fig. 1A shows the differences in the baseline characteristics between severe and non-severe COVID-19 patients. The severe patients were older and more frequently males and showed significant higher levels of C Reactive Protein (CRP), d-Dimer (D-D), Lactate Dehydrogenase (LDH), Neutrophil to Lymphocyte ratio (NLR) and Ferritin. Serum ferritin levels were positively correlated with severity of COVID-19 (Fig. 1B) and hyperferritinemia (ferritin level > 500 µg/L), was observed in all patients with severe disease on admission. Moreover, ROC curve analysis confirmed the excellent prognostic accuracies of serum Ferritin in discriminate patients with severe clinical conditions. (AUC 0.939, CI: 0,894 to 0,985 p < 0.001) (Fig. 1C). The triaging of COVID-19 patients is based on a combination of clinical, laboratory and instrumental parameters, mainly represented by Computed Tomography (CT). Thus, based on the severity of pulmonary impairment in CT scan and respiratory failure in need of mechanical ventilation, patients were further divided in 4 groups according to the WHO guidelines updated in May 20206Clinical management of COVID-19 - interim guidance (May 2020)-WHO - https://reliefweb.int/sites/reliefweb.int/files/resources/2005_clinical_management_of_covid-19-v7.pdfGoogle Scholar: 29 patients with no CT alterations (Group 0-mild); 32 patients with changes in CT scan no oxygen (Group 1-moderate); 38 patients with CT scan plus oxygen (Group 2-severe) and 42 patients with CT abnormalities plus intensive care unit (ICU) admission (critical-Group 3). Our data strongly confirm that increased levels of ferritin were directly related with the disease severity (Fig 2A). Particularly, not only severe group showed 2.6 times higher ferritin levels than the mild group, but patients who needed admission to the ICU showed 5.8 times higher ferritin compared to patients with mild COVID-19. Among all parameters considered, we also noted that the NLR was statistically correlated with the severity of disease. (Fig. 2B). Conversely, D-D, LDH and CRP increased only in the group of critical patients (group 3), being substantially stable in the other groups characterized by mild, moderate and severe disease (Fig. 2, panel C, D, E). Multivariate logistic regression model adjusted for several disease-related risk factors at admission, including age, sex, NLR, D-D, LDH, ferritin and CRP, demonstrated that serum ferritin resulted as an independent predictor of disease severity in COVID-19 patients (OR = 1,0048, 95% CI, 1,0029 to 1,0083, p < 0,001.). If patients were grouped according to the serum ferritin level with a cut off of 500 µg/ml derived from the HLH-20047Henter J.I. Horne A. Aricó M. et al.HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.Pediatr Blood Cancer. 2007; 48: 124-131https://doi.org/10.1002/pbc.21039Crossref PubMed Scopus (3493) Google Scholar criterion, hyperferritinemia accounted for 48,22% (68/141) of patients and the hyperferritinemia group had a higher proportion of severe cases (77,94% vs 10,30%, p < 0,001) than patients without hyperferritinemia. This is the first Italian report about the prognostic value of laboratory biomarkers considering 4 groups of mild, moderate, severe and critical patients with COVID-19. We clearly demonstrated that serum levels of ferritin progressively increased with the severity of disease and correlate with poor prognosis in COVID-19 patients. Increased ferritin levels could be indicative of a strong inflammatory reaction in COVID-19 and recent studies suggest that increased levels of circulating ferritin levels play a critical role by contributing to the development of a cytokine storm8Kernan K.F. Carcillo JA</b> Hyperferritinemia and inflammation.Int Immunol. 2017; 29: 401-409Crossref PubMed Scopus (301) Google Scholar,9Wessling-Resnick M. Crossing the iron gate: why and how transferrin receptors mediate viral entry.Annu Rev Nutr. 2018; 38: 431-458Crossref PubMed Scopus (88) Google Scholar resembling macrophage activating syndrome.10Shoenfeld Y. Corona (COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.Autoimmun Rev. 2020; 102538Crossref PubMed Scopus (161) Google Scholar Timely control of the cytokine storm in its early stage through immunomodulators and cytokine antagonists, as well as the reduction of lung inflammatory cell infiltration, is the key to improving the treatment success rate and reducing the mortality rate of patients with COVID-19. In this regard, ferritin evaluation could be an early, available and easy to use screening tool to assess the disease severity at the first admission in the emergency department. This test might be of crucial importance for the timely identification of patients at higher risk of an adverse outcome." @default.
• W3085384777 created "2020-09-21" @default.
• W3085384777 creator A5013937165 @default.
• W3085384777 creator A5021885457 @default.
• W3085384777 creator A5023820246 @default.
• W3085384777 creator A5036772495 @default.
• W3085384777 creator A5047858948 @default.
• W3085384777 creator A5048666084 @default.
• W3085384777 creator A5058185660 @default.
• W3085384777 creator A5060779246 @default.
• W3085384777 creator A5066867275 @default.
• W3085384777 date "2020-12-01" @default.
• W3085384777 modified "2023-10-11" @default.
• W3085384777 title "Serum Ferritin is an independent risk factor for Acute Respiratory Distress Syndrome in COVID-19" @default.
• W3085384777 cites W2162251899 @default.
• W3085384777 cites W2617626520 @default.
• W3085384777 cites W2805161384 @default.
• W3085384777 cites W3007189521 @default.
• W3085384777 cites W3011610993 @default.
• W3085384777 cites W3013816672 @default.
• W3085384777 cites W3015050005 @default.
• W3085384777 cites W3016127406 @default.
• W3085384777 cites W3036155640 @default.
• W3085384777 doi "https://doi.org/10.1016/j.jinf.2020.09.006" @default.
• W3085384777 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7490639" @default.
• W3085384777 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32946917" @default.
• W3085384777 hasPublicationYear "2020" @default.
• W3085384777 type Work @default.
• W3085384777 sameAs 3085384777 @default.
• W3085384777 citedByCount "44" @default.
• W3085384777 countsByYear W30853847772020 @default.
• W3085384777 countsByYear W30853847772021 @default.
• W3085384777 countsByYear W30853847772022 @default.
• W3085384777 countsByYear W30853847772023 @default.
• W3085384777 crossrefType "journal-article" @default.
• W3085384777 hasAuthorship W3085384777A5013937165 @default.
• W3085384777 hasAuthorship W3085384777A5021885457 @default.
• W3085384777 hasAuthorship W3085384777A5023820246 @default.
• W3085384777 hasAuthorship W3085384777A5036772495 @default.
• W3085384777 hasAuthorship W3085384777A5047858948 @default.
• W3085384777 hasAuthorship W3085384777A5048666084 @default.
• W3085384777 hasAuthorship W3085384777A5058185660 @default.
• W3085384777 hasAuthorship W3085384777A5060779246 @default.
• W3085384777 hasAuthorship W3085384777A5066867275 @default.
• W3085384777 hasBestOaLocation W30853847771 @default.
• W3085384777 hasConcept C116675565 @default.
• W3085384777 hasConcept C126322002 @default.
• W3085384777 hasConcept C141071460 @default.
• W3085384777 hasConcept C141983124 @default.
• W3085384777 hasConcept C159047783 @default.
• W3085384777 hasConcept C177713679 @default.
• W3085384777 hasConcept C203014093 @default.
• W3085384777 hasConcept C2777714996 @default.
• W3085384777 hasConcept C2778137277 @default.
• W3085384777 hasConcept C2778319317 @default.
• W3085384777 hasConcept C2779134260 @default.
• W3085384777 hasConcept C2909376813 @default.
• W3085384777 hasConcept C2909621147 @default.
• W3085384777 hasConcept C3006700255 @default.
• W3085384777 hasConcept C3007834351 @default.
• W3085384777 hasConcept C3008058167 @default.
• W3085384777 hasConcept C50440223 @default.
• W3085384777 hasConcept C524204448 @default.
• W3085384777 hasConcept C534529494 @default.
• W3085384777 hasConcept C71924100 @default.
• W3085384777 hasConceptScore W3085384777C116675565 @default.
• W3085384777 hasConceptScore W3085384777C126322002 @default.
• W3085384777 hasConceptScore W3085384777C141071460 @default.
• W3085384777 hasConceptScore W3085384777C141983124 @default.
• W3085384777 hasConceptScore W3085384777C159047783 @default.
• W3085384777 hasConceptScore W3085384777C177713679 @default.
• W3085384777 hasConceptScore W3085384777C203014093 @default.
• W3085384777 hasConceptScore W3085384777C2777714996 @default.
• W3085384777 hasConceptScore W3085384777C2778137277 @default.
• W3085384777 hasConceptScore W3085384777C2778319317 @default.
• W3085384777 hasConceptScore W3085384777C2779134260 @default.
• W3085384777 hasConceptScore W3085384777C2909376813 @default.
• W3085384777 hasConceptScore W3085384777C2909621147 @default.
• W3085384777 hasConceptScore W3085384777C3006700255 @default.
• W3085384777 hasConceptScore W3085384777C3007834351 @default.
• W3085384777 hasConceptScore W3085384777C3008058167 @default.
• W3085384777 hasConceptScore W3085384777C50440223 @default.
• W3085384777 hasConceptScore W3085384777C524204448 @default.
• W3085384777 hasConceptScore W3085384777C534529494 @default.
• W3085384777 hasConceptScore W3085384777C71924100 @default.
• W3085384777 hasIssue "6" @default.
• W3085384777 hasLocation W30853847771 @default.
• W3085384777 hasLocation W30853847772 @default.
• W3085384777 hasLocation W30853847773 @default.
• W3085384777 hasOpenAccess W3085384777 @default.
• W3085384777 hasPrimaryLocation W30853847771 @default.
• W3085384777 hasRelatedWork W1881743638 @default.
• W3085384777 hasRelatedWork W2420168943 @default.
• W3085384777 hasRelatedWork W3003901880 @default.
• W3085384777 hasRelatedWork W3004826915 @default.
• W3085384777 hasRelatedWork W3007868867 @default.
• W3085384777 hasRelatedWork W3020699490 @default.
• W3085384777 hasRelatedWork W3031607536 @default.

• next